Merck, Inc.
🇵🇭Philippines
A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
Phase 2
Terminated
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at BaselineDrug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at BaselineDrug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 39
- Registration Number
- NCT00924781
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Biological: Dalotuzumab 10 mg/kgBiological: CetuximabDrug: IrinotecanBiological: Dalotuzumab 15/7.5 mg/kg
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00925015
Study to Evaluate ATP-induced Pain and ATP-induced Dermal Vasodilation by Iontophoresis (0000-118)(COMPLETED)
Phase 1
Completed
- Conditions
- Osteoarthritis Pain
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00917696
A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)
Phase 1
Completed
- Conditions
- Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00914212
A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: MK-0941
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00912002
Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 168
- Registration Number
- NCT00910624
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00907738
The OBSTACLE Hypoglycemia Study (MK-0000-158)
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Sulfonylurea
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1069
- Registration Number
- NCT00907881
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
Phase 1
Terminated
- Conditions
- Myelogenous Leukemia, AcuteLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveLeukemia, Lymphocytic, AcuteMyelogenous Leukemia, Chronic, Aggressive Phase
- Interventions
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00907517
A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00902161
© Copyright 2025. All Rights Reserved by MedPath